monoclonal antibody news from FierceBiotech
News
EUSA Pharma spins off assets as it narrows focus
The transatlantic EUSA Pharma has spun off its monoclonal antibody research operation along with a development program for leukemia as it narrows its focus to late-stage drug development and Read more...
ALSO NOTED: FDA approves UCB's Cimzia; MacroChem acquires Virium; and much more...
> The FDA has approved UCB's monoclonal antibody Cimzia for the treatment of moderate to severe Crohn's disease. Cimzia's approval was Read more...
Stromedix gets $25M for mAb work
Cambridge, MA-based Stromedix has landed $25 million in a Series B round of venture capital. The company's lead drug is STX-100, a humanized monoclonal antibody which Stromedix is developing for Read more...
Inotek closes facilities, shakes up executive staff
There's a shakeup under way at Inotek. The Beverly, MA-based developer says it is closing several international sites and a pilot manufacturing facility in Israel as it focuses all of its efforts on Read more...
Shareholders stymie VaxGen, Raven merger
VaxGen and Raven Biotechnologies are backing out of their proposed merger after "stronger than anticipated opposition" from shareholders. The companies say that while they initially thought Read more...
Genitope suspends cancer work, looks to alternatives
After reviewing a failed late-stage trial of MyVax for Hodgkins lymphoma, Genitope has decided to suspend development work and focus on alternatives like its antibody program. MyVax had already Read more...
Morphotek licenses anti-cancer antibody
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead Read more...
SPOTLIGHT: Humira approved for juvenile RA
Humira approved for juvenile RAThe FDA has approved Abbott's Humira as a treatment for juvenile rheumatoid arthritis. This marks the sixth approved indication for Abbott's monoclonal antibody. Read more...
Sanofi to pay $500M for Dyax antibody program
Sanofi-Aventis has committed up to $500 million for the worldwide rights to Dyax's DX-2240 human monoclonal Read more...
Taligen raises a whopping $65M
Talk about big VC deals. Aurora, CO-based Taligen Therapeutics said today that it's expecting to receive Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets